激活NEDD4L通过促进EGFR蛋白质体降解来抑制EGFR驱动的肺腺癌生长
Maojian Chen1,2, Wei Jiang3, Jianhua Zhan1
1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Sun Yat-Sen university, Guangzhou, 510060, China.
准FOXM1/NEDD4L轴促进表皮生长因子受体 (EGFR) 降解,提供针对肺腺癌 (LUAD) 的新策略,并克服 osimertinib 耐药性. 组合疗法对EGFR突变性LUAD显示出希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- EGFR突变和放大驱动肺腺癌 (LUAD) 的生长,限制EGFR-氨酸激酶抑制剂 (TKI) 的疗效.
- 促进EGFR蛋白质降解是LUAD潜在的治疗策略.
研究的目的:
- 为了确定EGFR蛋白质体降解的媒介.
- 阐明控制LUAD中的EGFR降解的调节轴.
- 探索针对这一轴的治疗策略,以克服 osimertinib 耐药性.
主要方法:
- 数据库分析,qPCR,西斑,免疫光和共免疫沉确定了NEDD4L作为EGFR的E3泛基因酶.
- 生物信息学,双化酶记者分析和ChIP阐明了FOXM1在NEDD4L上的压制性作用.
- 虚拟查通过体外和体内活体功能研究确定了脊椎素作为FOXM1抑制剂.
主要成果:
- NEDD4L调解野生型和突变EGFR的蛋白质体降解,抑制LUAD的生长.
- FOXM1抑制了NEDD4L的表达,增加了EGFR水平,并促进了对 osimertinib的耐药性.
- 高FOXM1/低NEDD4L表达与糟糕的LUAD患者结果相关.
- 维特波芬抑制FOXM1,提高NEDD4L的调节,并克服奥西默提尼布的耐药性.
- 在LUAD模型中,verteporfin和osimertinib的组合表明了添加抑制作用.
结论:
- 在FOXM1/NEDD4L轴失调EGFR保护体降解,驱动LUAD的生长和抵抗.
- 通过FOXM1抑制激活NEDD4L为EGFR驱动的LUAD和 osimertinib耐药性提供了一个新的治疗策略.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
相关概念视频
Mitogens and the Cell Cycle
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
